Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides

Bioconjugate Chemistry

Volumn 22, Issue 8, 2011, Pages 1682-1689

  Guo, Haixun ^a   Lu, Jie ^a   Hathaway, Helen ^b,c   Royce, Melanie E ^b,c   Prossnitz, Eric R ^b,c   Miao, Yubin ^a,b,c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BINDING ENERGY; DISEASES; MEDICAL IMAGING; MONOCLONAL ANTIBODIES; PARTICLE BEAMS; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; TUMORS;

AMINO GROUP; BINDING AFFINITIES; D-LYSINE; GONADOTROPIN-RELEASING HORMONE; HORMONE RECEPTORS; HUMAN BREAST CANCER; MDA-MB-231; RECEPTOR BINDING; RECEPTOR TARGETING; TETRAACETIC ACID;

PEPTIDES;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID AMINOCAPROIC ACID INDIUM 111; DEXTRO LYSINE; DIAGNOSTIC AGENT; GONADORELIN RECEPTOR; LYSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CONJUGATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; IC 50; IMAGING; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; RECEPTOR BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; XENOGRAFT;

MUS MUSCULUS;

EID: 80051744241     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200252j     Document Type: Article

References (42)

1. Jemal, A., Siegel, R., Xu, J., and Ward, E. (2010) Cancer statistics CA Cancer J. Clin. 60, 277-300
2. Buist, D. S., Porter, P. L., Lehman, C., Taplin, S. H., and White, E. (2004) Factors contributing to mammography failure in women aged 40-49 years J. Natl. Cancer Inst. 96, 1432-1440 (Pubitemid 39429667)
3. Gambhir, S. S. (2002) Molecular imaging of cancer with positron emission tomography Nat. Rev. Cancer 2, 683-693 (Pubitemid 37328919)
4. Sharma, V., Luker, G. D., and Piwnica-Worms, D. (2002) Molecular imaging of gene expression and protein function in vivo with PET and SPECT J. Magn. Reson. Imaging 16, 336-351 (Pubitemid 35167870)
5. 18fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography J. Clin. Oncol. 20, 379-387 (Pubitemid 34072519)
6. 18F-FDG PET: histologic and immunohistochemical tissue analysis J. Nucl. Med. 42, 9-16 (Pubitemid 32104770)
7. Mankoff, D. A., Dunnwald, L. K., Gralow, J. R., Ellis, G. K., Charlop, A., Lawton, T. J., Schubert, E. K., Tseng, J., and Livingston, R. B. (2002) Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy J. Nucl. Med. 43, 500-509 (Pubitemid 34286345)
8. 18F]-D-glucose Cancer 90, 2227-2234 (Pubitemid 28240830)
9. Inoue, T., Yutani, K., Taguchi, T., Tamaki, Y., Shiba, E., and Noguchi, S. (2004) Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography J. Cancer Res. Clin. Oncol. 130, 273-278 (Pubitemid 38680268)
10. Avril, N., Rose, C. A., Schelling, M., Dose, J., Kuhn, W., Bense, S., Weber, W., Ziegler, S., Graeff, H., and Schwaiger, M. (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations J. Clin. Oncol. 18, 3495-3502
11. 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer J. Clin. Oncol. 19, 3516-3523 (Pubitemid 32730089)
12. Isasi, C. R., Moadel, R. M., and Blaufox, M. D. (2005) A meta-analysis of FDG PET for the evaluation of breast cancer recurrence and metastases Breast Cancer Res. Treat. 90, 105-112 (Pubitemid 40568893)
13. Lonneux, M., Borbath, I. I., Berliere, M., Kirkove, C., and Pauwels, S. (2000) The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer Clin. Positron Imaging 3, 45-49
14. Vranjesevic, D., Filmont, J. E., Meta, J., Silverman, D. H., Phelps, M. E., Rao, J., Valk, P. E., and Czernin, J. (2002) Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients J. Nucl. Med. 43, 325-329 (Pubitemid 34208093)
15. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions J. Clin. Oncol. 16, 3375-3379 (Pubitemid 28481635)
16. Miller, W. R., Scott, W. N., Morris, R., Fraser, H. M., and Sharpe, R. M. (1985) Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist Nature 313, 231-233 (Pubitemid 15194060)
17. Eidne, K. A., Flanagan, C. A., and Millar, R. P. (1985) Gonadotropin-releasing hormone binding sites in human breast carcinoma Science 229, 989-991 (Pubitemid 16248494)
18. Sharoni, Y., Bosin, E., Miinster, A., Levy, J., and Schally, A. V. (1989) Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone Proc. Natl. Acad. Sci. U.S.A. 86, 1648-1651 (Pubitemid 19078959)
19. Fekete, M., Wittliff, J. L., and Schally, A. V. (1989) Characteristics and distribution of receptors for [d-Trp6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer J. Clin. Lab. Anal. 3, 137-147 (Pubitemid 20199263)
20. Baumann, K. H., Kiesel, L., Kaufmann, M., Bastert, G., and Runnebaum, B. (1993) Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters Breast Cancer Res. Treat. 25, 37-46 (Pubitemid 23107734)
21. Millar, R. P. (2005) GnRH and GnRH receptors Anim. Reprod. Sci. 88, 5-28
22. Beckers, T., Bernd, M., Kutscher, B., Kuhne, R., Hoffman, S., and Reissmann, T. (2001) Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor Biochem. Biophys. Res. Commun. 289, 653-663 (Pubitemid 33152283)
23. Nagy, A., Schally, A. V., Armatis, P., Szepeshazi, K., Halmos, G., Kovacs, M., Zarandi, M., Groot, K., Miyazaki, M., Jungwirth, A., and Horvath, J. (1996) Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent Proc. Natl. Acad. Sci. U.S.A. 93, 7269-7273 (Pubitemid 26243538)
24. Halmos, G., Nagy, A., Lamharzi, N., and Schally, A. V. (1999) Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers Cancer Lett. 136, 129-136 (Pubitemid 29164387)
25. Wang, X., Krebs, L. J., Al-Nuri, M., Pudavar, H. E., Ghosal, S., Liebow, C., Nagy, A. A., Schally, A. V., and Prasad, P. N. (1999) A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapy Proc. Natl. Acad. Sci. U.S.A. 96, 11081-11084 (Pubitemid 29487336)
26. Szepeshazi, K., Schally, A. V., Nagy, A., Halmos, G., and Groot, K. (1997) Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs inhibit growth of estrogen-independent MXT mouse mammary cancer in vivo by decreasing cell proliferation and inducing apoptosis Anticancer Drugs 8, 974-987 (Pubitemid 28027096)
27. Szepeshazi, K., Schally, A. V., and Nagy, A. (1999) Effective treatment of advanced estrogen-independent MXT mouse mammary cancers with targeted cytotoxic LH-RH analogs Breast Cancer Res. Treat. 56, 267-276 (Pubitemid 29495657)
28. Kahan, Z., Nagy, A., Schally, A. V., Halmos, G., Arencibia, J. M., and Groot, K. (1999) Complete regression of MX-1 human breast cancer xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207 Cancer 85, 2608-2615 (Pubitemid 29272747)
29. Bajo, A. M., Schally, A. V., Halmos, G., and Nagy, A. (2003) Targeted doxorubicincontaining luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers Clin. Cancer Res. 9, 3742-3748 (Pubitemid 37169243)
30. Kahan, Z., Nagy, A., Schally, A. V., Halmos, G., Arencibia, J. M., and Groot, K. (2000) Administration of a targeted cytotoxic analog of luteinizing hormone releasing hormone inhibits growth of estrogen independent MDA-MB-231 human breast cancers in nude mice Breast Cancer Res. Treat. 59, 255-262 (Pubitemid 30243047)
31. Chatzistamou, I., Schally, A. V., Nagy, A., Armatis, P., Szepeshazi, K., and Halmos, G. (2000) Effective treatment of metastatic MDA-MD-435 human estrogen independent breast carcinomas with a targeted cytotoxic analog of luteinizing hormone-releasing hormone, AN-207 Clin. Cancer Res. 6, 4158-4165
32. Flanagan, C. A., Fromme, B. J., Davidson, J. S., and Millar, R. P. (1998) A high affinity gonadotropin-releasing hormone (GnRH) tracer, radioiodinated at position 6, facilitates analysis of mutant GnRH receptors Endocrinology 139, 4115-4119 (Pubitemid 28513696)
33. Guo, H., Yang, J., Gallazzi, F., and Miao, Y. (2010) Reduction of the ring size of radiolabeled lactam bridige-cyclized α-MSH peptide, resulting in enhanced melanoma uptake J. Nucl. Med. 51, 418-426
34. Scopinaro, F., Varvarigou, A. D., Ussof, W., De Vincentis, G., Sourlingas, T. G., Evangelatos, G. P., Datsteris, J., and Archimandritis, S. C. (2002) Technetium-labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients Cancer Biother. Radiopharm. 17, 327-335 (Pubitemid 34765055)
35. Van de Wiele, C., Dumont, F., Broecke, R. V., Oosterlinck, W., Cocquyt, V., Serreyn, R., Peers, S., Thornback, J., Slegers, G., and Dierck, R. A. (2000) Technetium-99m RP527, a GRP analogue for visualization of GRP receptor-expressing malignancies: a feasibility study Eur. J. Nucl. Med. 27, 1694-1699
36. 2]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors Nucl. Med. Biol. 36, 171-181
37. 2] conjugates for targeting gastrin-releasing peptide receptors overexpressed on breast carcinoma Anticancer Res. 30, 19-30
38. 188Re of peptide, conjugates containing a dithia-bisphosphine chelating agent Bioconjugate Chem. 12, 354-63 (Pubitemid 32467777)
39. 99mTc labeled GnRH analog as potential SPECT molecular imaging agent in cancer Nucl. Med. Biol. 31, 921-933 (Pubitemid 39297690)
40. 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency Bioconjugate Chem. 19, 1256-1268 (Pubitemid 351874949)
41. 111In-labeled lactam bridge-cyclized alpha-melanocyte stimulating hormone peptide Bioconjugate Chem. 20, 2162-2168
42. 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells J. Nucl. Med. 44, 823-831 (Pubitemid 39655218)